DNA primase subunit 1 deteriorated progression of hepatocellular carcinoma by activating AKT/mTOR signaling and UBE2C-mediated P53 ubiquitination
Open Access
- 23 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell & Bioscience
- Vol. 11 (1), 1-19
- https://doi.org/10.1186/s13578-021-00555-y
Abstract
DNA primase subunit 1 (PRIM1) has been reported as a novel oncogene in several cancer types. However, its roles in hepatocellular carcinoma (HCC) remain unclear. This study aimed to investigate underlying mechanisms of PRIM1 and identify it as a potential molecular target for HCC. Hub genes were screened between HCC tissues and normal liver tissues in 3 gene expression omnibus (GEO) datasets and the cancer genome atlas (TCGA). The expression features and prognostic value of one of the hub genes PRIM1 were analyzed by bioinformatic analyses and immunohistochemistry. Loss-of-function and gain-of-function studies were used to investigate the regulatory role of PRIM1 in HCC cells. Real-time (RT)-qPCR, western blotting, and ubiquitin immunoprecipitation assays were performed to explore the underlying mechanisms. The xenograft model was employed to detect the roles of PRIM1 in tumor growth in vivo. Finally, the 3D spheroid model was conducted to validate the role of PRIM1 in tumor growth and sorafenib resistance. The hub genes of HCC were screened in multiple bioinformatic datasets. PRIM1, as one of the hub genes, was significantly overexpressed in HCC tissues in mRNA and protein levels. In addition, high expression of PRIM1 indicated poor prognosis of HCC patients in TCGA, ICGC, and Nantong cohorts. Overexpression of PRIM1 promoted the proliferation, migration/invasion, and sorafenib resistance of HCC cells, with the decrease in apoptosis and cell cycle arrest. Mechanically, PRIM1 facilitated epithelial-mesenchymal transition (EMT) process and the activity of PI3K/AKT/mTOR signaling of HCC cells. Additionally, PRIM1 could cause the ubiquitination and degradation of P53 by upregulating Ubiquitin Conjugating Enzyme E2 C (UBE2C). Furthermore, knockdown of PRIM1 significantly inhibited the growth of xenograft tumors and HCC cells-derived spheroids with enhanced sorafenib resistance. This study implies that PRIM1 may play a key role in the progression of HCC and may serve as a potential target for HCC treatment.Funding Information
- National Natural Science Foundation of China (82070622, 81702419)
- Jiangsu Provincial Key Research and Development Program (BE2020668)
- Nantong Science and Technology Bureau (MS12019013, MS12020020)
This publication has 29 references indexed in Scilit:
- DNA primase polypeptide 1 (PRIM1) involves in estrogen‐induced breast cancer formation through activation of the G2/M cell cycle checkpointInternational Journal of Cancer, 2018
- Hepatocellular carcinomaThe Lancet, 2018
- The biology of Hepatocellular carcinoma: implications for genomic and immune therapiesMolecular Cancer, 2017
- Variation analysis of PRIM1 gene in Chinese patients with primary ovarian insufficiencyReproductive BioMedicine Online, 2016
- Crystal Structure of the Human PrimaseOnline Journal of Public Health Informatics, 2015
- Mutation of DNA primase causes extensive apoptosis of retinal neurons through the activation of DNA damage checkpoint and tumor suppressor p53Development, 2008
- Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin‐conjugating enzyme E2C gene expressionInternational Journal of Cancer, 2007
- Amplifications of DNA primase 1 (PRIM1) in human osteosarcomaGenes, Chromosomes and Cancer, 1999
- Primase Activity of Human DNA Polymerase α-PrimaseOnline Journal of Public Health Informatics, 1998
- Assignment of the 49-kDa (PRIM1) and 58-kDa (PRIM2A and PRIM2B) Subunit Genes of the Human DNA Primase to Chromosome Bands 1q44 and 6p11.1-p12Genomics, 1995